Q-omics provides the consensus-scored UBE2R2-AS1 profile across patient tissues and cancer cell-line models. UBE2R2-AS1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UBE2R2-AS1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, UBE2R2-AS1 RNA expression shows 16,870 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where UBE2R2-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2R2-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2R2-AS1 survival associations across molecular data types. UBE2R2-AS1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2R2-AS1 RNA expression–survival associations across cancer types. High UBE2R2-AS1 expression shows unfavorable associations in KIRC, LIHC, ACC, UCEC and LUSC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UBE2R2-AS1 RNA expression.
This table summarizes UBE2R2-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2R2-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2R2-AS1 shows lower tumor expression in THCA and KIRC and higher tumor expression in COAD, ESCA, STAD and CHOL. The COAD box plot shows higher UBE2R2-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.887, t-test p < 0.001).
This table shows molecular features associated with UBE2R2-AS1 in patient tissues and cancer cell lines. In patient samples, UBE2R2-AS1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
